专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07834140B2 Polypeptide fragment of constitutive coactivator of PPARgamma 失效
标题翻译： PPARgamma的组成共激活因子的多肽片段
公开(公告)号：US07834140B2
公开(公告)日：2010-11-16
申请号：US11870736
申请日：2007-10-11
申请人： Dechun Li
发明人： Dechun Li
IPC分类号： A61K38/00 , A01N37/18
CPC分类号： C07K14/4705 , C07K16/18 , C12N15/113 , C12N2310/14 , G01N33/5041 , G01N2333/70567
摘要： This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPARγ. and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed herein is a novel polypeptide coactivator of PPARγ, and fragments thereof, which possess coactivator or corepressor activity. Also related are nucleotide sequences which express these polypeptides. Also disclosed is an interfering RNA that may be used to inhibit adipogenesis.
摘要翻译：本发明一般涉及利用核受体调节细胞中脂肪生成的组合物和方法。具体地，本发明涉及调节转录因子PPARγ的组合物。并且增强或抑制负责将细胞分化导向脂肪形成途径的基因的转录。更具体地，本文公开了具有共激活剂或共抑制因子活性的PPARγ的新型多肽共活化剂及其片段。还涉及表达这些多肽的核苷酸序列。还公开了可用于抑制脂肪形成的干扰RNA。

32. 发明申请

US20100266610A1 AUTO-ANTIBODY MARKERS OF AUTOIMMUNE DISEASE 审中-公开
标题翻译：自动免疫疾病的自动抗体标记
公开(公告)号：US20100266610A1
公开(公告)日：2010-10-21
申请号：US12598524
申请日：2008-05-05
申请人： Jonathan Zmuda , Christina Strange , Wendy White
发明人： Jonathan Zmuda , Christina Strange , Wendy White
IPC分类号： A61K39/395 , G01N33/53 , A61P37/00 , A61P17/06
CPC分类号： G01N33/564 , C07K16/2857 , G01N2333/70567
摘要： The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.
摘要翻译：本发明包括与自身免疫疾病相关的自身抗体。自身抗体可以用于例如治疗患者的方法，诊断患者的方法，监测患者的疾病进展的方法以及患者预后的方法。

33. 发明申请

US20100105645A1 INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS 有权
标题翻译：通过特异性卵母细胞瘤抑制PPAR GAMMA表达
公开(公告)号：US20100105645A1
公开(公告)日：2010-04-29
申请号：US12520281
申请日：2007-12-19
申请人： Farhad Parhami , Woo-Kyun Kim , Michael E. Jung , Khanhlinh Nguyen
发明人： Farhad Parhami , Woo-Kyun Kim , Michael E. Jung , Khanhlinh Nguyen
IPC分类号： A61K31/56 , C12N5/02 , C12Q1/68 , C12N5/071 , G01N33/53
CPC分类号： A61K31/57 , C07J1/00 , G01N2333/70567 , G01N2500/00 , G01N2500/10
摘要： This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression.
摘要翻译：本发明涉及使用试剂抑制过氧化物酶体增殖物激活受体表达的方法。

34. 发明申请

US20090252716A1 METHODS FOR IDENTIFYING NUCLEAR RECEPTOR/LIGAND COMBINATIONS FOR TARGETING BRAIN TUMOR STEM CELLS AND FOR THEIR USE 审中-公开
标题翻译：鉴定用于靶向脑肿瘤干细胞的核细胞受体/配体组合的方法及其使用
公开(公告)号：US20090252716A1
公开(公告)日：2009-10-08
申请号：US12417689
申请日：2009-04-03
申请人： John J. Bright
发明人： John J. Bright
IPC分类号： A61K31/7076 , C12Q1/02 , A61K31/4045 , A61K31/496 , A61K31/429 , A61K31/195 , A61K31/5575 , A61P35/00
CPC分类号： A61K31/195 , A61K31/4045 , A61K31/429 , A61K31/496 , A61K31/5575 , A61K31/7076 , G01N33/5073 , G01N33/57407 , G01N33/57496 , G01N33/6875 , G01N2333/70567
摘要： An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's), is capable of inhibiting cell proliferation. Once the nuclear receptor/ligand combination has been identified, it can be utilized in vitro and in vivo to inhibit the proliferation and survival of the cancerous stem cells and ultimately affect proliferation and survival of tumors. The method can be utilized alone or in combination with other treatment methods. The method can also be utilized with regard to other forms of cancer which have cancerous stem cells associated therewith and which abnormally express one or more nuclear receptors.
摘要翻译：提供了用于鉴定由脑肿瘤干细胞异常表达的核受体的体外方法和相应的配体，如果施用于脑肿瘤干细胞（BTSC），其能够抑制细胞增殖。一旦核受体/配体组合已被鉴定，其可以在体外和体内被用于抑制癌性干细胞的增殖和存活并最终影响肿瘤的增殖和存活。该方法可以单独使用或与其他治疗方法组合使用。该方法也可以用于与其相关的癌性干细胞并且异常表达一种或多种核受体的其它形式的癌症。

35. 发明申请

US20090203537A1 NUCLEAR RECEPTOR ASSAY 有权
标题翻译：核受体测定
公开(公告)号：US20090203537A1
公开(公告)日：2009-08-13
申请号：US12309716
申请日：2007-09-10
申请人： Robby Ruijtenbeek , Rene Houtman , Marinus Gerardus Johannes Van Beuningen
发明人： Robby Ruijtenbeek , Rene Houtman , Marinus Gerardus Johannes Van Beuningen
IPC分类号： C40B30/04
CPC分类号： G01N33/566 , C40B30/04 , G01N2333/70567 , G01N2333/723 , G01N2500/02
摘要： The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay.
摘要翻译：本发明涉及用于测量核受体 - 共调节因子相互作用的化合物功效和效力的方法，包括以下步骤：（a）在允许相互作用的条件下共培养至少一种核受体和至少一种化合物; （b）在允许复合调节的受体共调节因子相互作用的条件下，共同孵育步骤（a）的核受体 - 化合物混合物与共调节子阵列; （c）协调调节剂浓度的功能B中化合物调节的受体 - 共调节因子相互作用的测定，以及（d）化合物浓度作用下化合物调节的受体 - 共调节物相互作用的测定; 其中步骤（c）和（d）在单次测定中进行。

36. 发明申请

US20060141543A1 Cellular retinoic acid binding protein II as a marker for breast cancer 失效
公开(公告)号：US20060141543A1
公开(公告)日：2006-06-29
申请号：US11294176
申请日：2005-12-05
申请人： Gabriele Pestlin , Herbert Andres , Peter Berndt , Marie-Luise Hagmann , Johann Karl , Hanno Langen , Werner Zolg
发明人： Gabriele Pestlin , Herbert Andres , Peter Berndt , Marie-Luise Hagmann , Johann Karl , Hanno Langen , Werner Zolg
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N33/57473 , G01N2333/70567
摘要： The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.

37. 发明申请

US20060101530A1 Rors as modifiers of the p21 pathway and methods of use 审中-公开
标题翻译：作为p21途径的修饰剂和使用方法
公开(公告)号：US20060101530A1
公开(公告)日：2006-05-11
申请号：US10528032
申请日：2003-09-15
申请人： Helen Francis-Lang , Lori Friedman , Thomas Kidd , Siobhan Roche , Haiquang Zhang
发明人： Helen Francis-Lang , Lori Friedman , Thomas Kidd , Siobhan Roche , Haiquang Zhang
IPC分类号： A01K67/027 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要： Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译：人类ROR基因被鉴定为p21途径的调节剂，因此是与缺陷型p21功能相关的疾病的治疗靶点。提供了用于鉴定p21调节剂的方法，包括筛选调节ROR活性的药剂。

38. 发明申请

US20060040321A1 Orphan receptor TLX and uses therefor 审中-公开
标题翻译：孤儿受体TLX并用于此
公开(公告)号：US20060040321A1
公开(公告)日：2006-02-23
申请号：US11096072
申请日：2005-03-31
申请人： Yanghong Shi , Ruth Yu , Fred Gage , Ronald Evans
发明人： Yanghong Shi , Ruth Yu , Fred Gage , Ronald Evans
IPC分类号： G01N33/53 , C07H21/04 , C07K14/705 , C12N5/08
CPC分类号： C07K14/70567 , G01N2333/70567
摘要： In accordance with the present invention, there are provided methods for identifying compounds which modulate the activity of TLX. Such compounds will find use in a wide variety of applications, e.g., methods for relieving TLX-mediated transcription repression and/or inducing processes mediated by TLX, methods for inhibiting processes mediated by TLX, methods for promoting stem cell differentiation in a system in need thereof, and the like. In accordance with additional aspects of the present invention, there are provided methods for identifying compounds which modulate the expression of TLX. Such compounds will find use in a variety of applications, e.g., methods for treating neurodegenerative diseases in a subject in need thereof; methods for reversing the reduction of neurogenesis from neural stem cells in a subject in need thereof; methods for promoting generation of neural cell populations in a subject in need thereof; methods for maintaining adult neural stem cells in an undifferentiated, proliferative state; methods for rescuing neural stem cell activity in a system in need thereof; methods for promoting neural stem cell activity in a system in need thereof; and the like.
摘要翻译：根据本发明，提供了鉴定调节TLX活性的化合物的方法。这样的化合物可用于各种各样的应用，例如用于缓解由TLX介导的TLX介导的转录抑制和/或诱导过程的方法，用于抑制由TLX介导的过程的方法，用于在需要的系统中促进干细胞分化的方法等等。根据本发明的另外的方面，提供了鉴定调节TLX表达的化合物的方法。这些化合物将用于各种应用，例如用于治疗有需要的受试者中的神经变性疾病的方法; 在有需要的受试者中逆转神经干细胞的神经发生减少的方法; 用于促进有需要的受试者中神经细胞群的产生的方法; 保持成年神经干细胞处于未分化增殖状态的方法; 在有需要的系统中拯救神经干细胞活性的方法; 用于在有需要的系统中促进神经干细胞活性的方法; 等等。

39. 发明申请

US20060024844A1 Method for the idenification of ligands 审中-公开
标题翻译：配体鉴定方法
公开(公告)号：US20060024844A1
公开(公告)日：2006-02-02
申请号：US10522660
申请日：2002-09-20
申请人： Dionisios Rentzeperis , Hossein Askari , Barry Springer , Roger Bone , Francis Salemme
发明人： Dionisios Rentzeperis , Hossein Askari , Barry Springer , Roger Bone , Francis Salemme
IPC分类号： G01N33/543 , G06F19/00 , G01N33/48 , G01N33/50
CPC分类号： C40B30/04 , G01N33/566 , G01N33/68 , G01N33/6803 , G01N33/6845 , G01N2333/4703 , G01N2333/70567 , G01N2333/723 , G01N2333/726 , G01N2333/9121 , G01N2500/00
摘要： The present invention relates generally to a method of identifying ligands that modulate protein-protein interactions. More particularly, the present invention relates to methods of determining agonists or antagonists of a co-regulator dependent target molecule based on the ability to modify the stability of the target molecule.
摘要翻译：本发明一般涉及鉴定调节蛋白质 - 蛋白质相互作用的配体的方法。更具体地，本发明涉及基于调节靶分子的稳定性的能力来确定共调节因子依赖性靶分子的激动剂或拮抗剂的方法。

40. 发明申请

US20050142634A1 Novel modulator of non-genomic activity of nuclear receptors (mnar) and uses thereof 审中-公开
标题翻译：核受体的非基因组活性的新型调节剂（mnar）及其用途
公开(公告)号：US20050142634A1
公开(公告)日：2005-06-30
申请号：US10473753
申请日：2002-04-03
申请人： Boris Cheskis , Elliott Nickbarg , Chi-Wai Wong
发明人： Boris Cheskis , Elliott Nickbarg , Chi-Wai Wong
IPC分类号： A01K67/027 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/74 , C07H21/04 , C07K14/72 , C12N1/18
CPC分类号： C07K16/18 , C07K14/4702 , G01N33/743 , G01N2333/70567 , G01N2333/723
摘要： A novel protein modulator of non-genomic activity of nuclear receptors (MNAR), which interacts with estrogen receptors alpha (ERα), estrogen receptor beta (ERβ), and other nuclear receptors, was discovered and characterized. An MNAR-ER complex, in vitro and in vivo, relates to nucleic acids, antisense, recombinant expression of nucleic acids, as well as host cells, compositions and assays that utilize the nucleic acids and protein of this invention.
摘要翻译：发现并表征了与雌激素受体α（ERalpha），雌激素受体β（ERbeta）和其他核受体相互作用的核受体（MNAR）的非基因组活性的新型蛋白质调节剂。在体外和体内的MNAR-ER复合物涉及核酸，核酸的反义重组表达，以及利用本发明的核酸和蛋白质的宿主细胞，组合物和测定法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式